Author: Francis Gordon
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.3, Iss.4, 2004-07, pp. : 289-303
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis
By Ziemssen T.
Drug Safety, Vol. 24, Iss. 13, 2001-01 ,pp. :
Interferon-β-1b of benefit in early multiple sclerosis
Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. :
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
CNS Drugs, Vol. 25, Iss. 6, 2011-06 ,pp. :